#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Non-small cell lung cancer metastatic Asthma Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Leukodystrophy Pleomorphic liposarcoma Endometrial adenocarcinoma Anaplastic large cell lymphoma T- and null-cell types Non-small cell lung cancer Neoplasm malignant Anti-myelin-associated glycoprotein associated polyneuropathy Neuroendocrine carcinoma of the skin Peritoneal neoplasm Neuroendocrine tumour of the lung Paraneoplastic neurological syndrome Cutaneous T-cell lymphoma refractory Familial amyotrophic lateral sclerosis Ehlers-Danlos syndrome Anti-myelin-associated glycoprotein antibodies positive More trials…

    Learn about Rare Diseases

    Mucopolysaccharidosis III – Basic Information Osteosarcoma metastatic – Life with Disease SAPHO syndrome – Trials in Disease Osteosarcoma recurrent – Basic Information Vascular malformation Prolymphocytic leukaemia – Trials in Disease CADASIL – Treatment Progressive multifocal leukoencephalopathy – Life with Disease Acquired haemophilia – Basic Information Proteus syndrome More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Desoximetasone Imatinib Cefixime Glipizide Img-007 Gen3017 Technetium (99Mtc) Vib1116 Etanercept Aluminium Febuxostat RP3 Ion440 Gabapentin Defactinib CAL101 AZD0022 Clebopride Hydrogen Maleate Alxn2220 Op-1250 More therapies…

    Learn about Your Condition

    Menopause Biliary neoplasm Injury Fatty acid oxidation disorder Childhood asthma Neurofibrosarcoma Rectal neoplasm Skin candida Genitourinary tract neoplasm Pericarditis Sickle cell anaemia Device related infection Bronchostenosis Testicular leiomyosarcoma Ureteric cancer More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Dermatitis atopic

  • Effectiveness and Safety of Abrocitinib in Children 6 to Under 12 Years with Moderate-to-Severe Atopic Dermatitis

    Recruiting

    3 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Abrocitinib
    Germany Hungary Poland Spain

  • Study Comparing Methylprednisolone Aceponate Creams and a Non-Active Cream for Patients with Mild to Moderate Atopic Dermatitis

    Recruiting

    3 1 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Methylprednisolone Aceponate
    Germany

  • Study on Amlitelimab for Patients Aged 12 and Older with Moderate to Severe Atopic Dermatitis Using Topical Corticosteroids and Inadequate Response to Previous Treatments

    Recruiting

    3 1 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Amlitelimab
    • Pimecrolimus
    • Tacrolimus
    France Germany Greece Italy The Netherlands Poland +1

  • Study on Long-Term Safety and Efficacy of Amlitelimab for Patients with Moderate to Severe Atopic Dermatitis from Previous Trials

    Recruiting

    4 1 1 1
    Investigated Drugs:
    • Amlitelimab
    Bulgaria Czechia Denmark France Germany Greece +7

  • Study on Atopic Dermatitis Treatment with Baricitinib, Tralokinumab, Abrocitinib, Upadacitinib, and Dupilumab for Patients Needing Second-Line Systemic Therapy

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Abrocitinib
    • Tralokinumab
    • Dupilumab
    Spain

  • A study to evaluate the long-term safety and effectiveness of afimkibart in patients with atopic dermatitis who took part in previous afimkibart studies

    Recruiting

    2 1
    Investigated Drugs:
    • Ro7790121
    France Germany Italy Poland Spain
Previous Page
1 2 3 4 … 14
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!